Morrisville, NC, United States
Morrisville, NC, United States

Time filter

Source Type

News Article | February 15, 2017
Site: phys.org

The research was carried out by Keele's Dr Sharon Owen, Dr Heidi Fuller, Mr Phil Jones and Professor Sally Roberts at the RJAH Orthopaedic Hospital in Oswestry, part of Keele University's Institute of Science and Technology in Medicine, and assisted by scientists in Cardiff and St Andrew's Universities. The study, published in this month's Bioscience Reports, found that commercial reagents, which were purchased from highly respected companies, were not pure but contained many contaminants which had a huge and potentially misleading effect on the scientists' work. Professor Roberts said: "We have found that commercial preparations of these particular chemicals were very impure, containing many other components which actually affected our results. "We came by these findings by chance as our laboratory purchased the biomolecules from a well-established supplier to investigate their effect on nerve cells but anomalous results forced us to test their purity. We were studying what controls nerves growing into patients' intervertebral discs to try and help us understand what causes back pain in a particular group of people. "Using mass spectrometry and qualitative Western blotting, we discovered unacceptable contamination with other biologically active molecules. "Reagents that are misleadingly labelled can waste researchers' funds and time. Testing these molecules can be very expensive and time consuming and not all scientists will have the equipment or finances to do so. One purchase costs hundreds of pounds for just a few milligrams and then for it to be impure is even more costly, because it wastes valuable research time and other resources. "Most importantly the wrong results can distort important scientific experiments. What is interesting is that many branches of science and medicine have been looking at this molecule (and bought the same material as we did from the same company), ranging from glaucoma and diseases in the eye to studies on malaria. "It's very important for scientists to be aware of this when buying commercial reagents." Unfortunately, the effect of these impurities may have already interfered with experiments leading to inaccurate conclusions and reports by scientists. Explore further: Milestone for the analysis of human proteomes More information: Sharon J. Brown et al. Contaminants in commercial preparations of 'purified' small leucine-rich proteoglycans may distort mechanistic studies, Bioscience Reports (2017). DOI: 10.1042/BSR20160465


News Article | February 22, 2017
Site: www.eurekalert.org

The first known case of artemisinin-resistance in Africa has been identified: a finding of great significance for efforts in global malaria control and drug resistance monitoring. A large international team that included KAUST scientists identified the African origin of drug-resistant malaria parasites detected in a Chinese patient, who had travelled from Equatorial Guinea to China1. Artemisinin-based combination therapy (ACT) is the first-line recommended malaria treatment and comprises artemisinin andd another antimalarial drug. Normally ACT clears the parasites from the blood within three days; however, recently, strains of the malaria-causing agent, Plasmodium falciparum, in Southeast Asia have become relatively tolerant to artemisinin. The resistance is partial and the majority of patients can be cured, albeit with a considerable delay. But, malariologists, including experts from the World Health Organization, fear that P. falciparum might eventually develop complete resistance to artemisinin, as it has to other antimalarials. The study, led by Jun Cao from the Jiangsu Institute for Parasitic Diseases, China, confirmed that the parasite carried a new mutation in a gene called Kelch13 (K13), the main driver for artemisinin resistance in Asia. Then, Arnab Pain, KAUST Professor of Bioscience, and his Ph.D. student Abhinay Ramaprasad set out to determine whether the parasite originated from Africa or Southeast Asia. "We used whole-genome sequencing and bioinformatics tools we had previously developed--like detectives trying to link the culprit parasite to the crime scene," explained Pain. Sequencing and analysis of P. falciparum DNA unveiled its origin by disclosing the several one-nucleotide differences, called single nucleotide polymorphisms (SNPs) that vary according to the geographical source of the strain. In the same way as merchandise barcodes contain information about the country of a product's origin, SNP patterns reveal the birthplace of the parasite. For these tests, KAUST scientists used the nuclear DNA, as well as the one present in two organelles of the parasite: the mitochondrium and the apicoplast, a defining organelle of malaria parasites and related species. Both methods independently validated the origin of the parasite as West African, confirming the first case of artemisinin-resistance mediated by a K13 gene mutation on the African continent. "The spread of artemisinin resistance in Africa would be a major setback in the fight against malaria, as ACT is the only effective and widely used antimalarial treatment at the moment. Therefore, it is very important to regularly monitor artemisinin resistance worldwide," explained Pain.


News Article | March 2, 2017
Site: www.businesswire.com

PHOENIX--(BUSINESS WIRE)--Jack B. Jewett will retire as Flinn Foundation president and CEO at the end of September, concluding more than eight years of service in which the foundation expanded and enhanced its program areas to better serve Arizona. Russell Reynolds Associates, an international executive search firm, has been hired by the foundation to conduct a national search to replace Jewett. The new CEO is expected to be named this summer. Jewett was hired in 2009 as the second CEO in the history of the Phoenix-based private, nonprofit grantmaking organization after a long career as an Arizona leader in health care, education and public policy, with extensive community involvement. He had previously served on the Arizona Board of Regents from 1998-2006, including a term as president; served five terms in the Arizona House of Representatives, from 1983-1992; held senior public policy and government relations positions with Tucson Medical Center for 13 years; and was president of Territorial Newspapers, a family-owned publishing and printing company in Tucson. As CEO, Jewett saw the need for a new initiative to cultivate civic leadership at a statewide level to assure a strong future for Arizona. The nonpartisan Arizona Center for Civic Leadership and its flagship Flinn-Brown Academy, established in 2010, was the philanthropic response to this need. Today, the Flinn-Brown Network of current and future state-level leaders from all walks of life is 260 members strong. This program joined the foundation’s continued dedication to supporting the biosciences, arts and culture, and the Flinn Scholars Program, a merit-based scholarship awarded to Arizona’s top high-school seniors to attend one of Arizona’s public universities. The biosciences have remained the preeminent target of the foundation’s grantmaking. Under Jewett’s leadership, the foundation started a Bioscience Entrepreneurship Program to benefit promising Arizona startup firms, updated Arizona’s Bioscience Roadmap to continue the long-term strategic plan, launched a new direction in arts giving focused on bringing financial stability to organizations, celebrated the foundation’s 50th anniversary, and enhanced the Scholars Program by offering professional internships to Scholars at leading Arizona businesses and organizations. “Jack has provided tremendous leadership to the foundation and to Arizona over many years,” said Dr. David J. Gullen, chair of the Flinn Foundation board of directors. “Flinn’s new initiatives during his tenure have complemented and strengthened the foundation’s longtime goals and programs.” Jewett was hired in the midst of a deep recession, when the foundation’s endowment, as was the case throughout the philanthropic sector, was suffering. The foundation never canceled or reduced grant awards, or reduced staff, and the endowment has recovered to more than $200 million. Carefully targeted recent grants have supported major collaborative initiatives led by organizations such as Banner Alzheimer's Institute, Critical Path Institute and Translational Genomics Research Institute, as well as the state’s three public universities and a number of Arizona’s largest arts-and-culture organizations. “Today, the Flinn Foundation is in excellent condition financially and programmatically, and opportunities abound for the foundation to play its proven pivotal roles of catalyzing, convening and grantmaking, and have a substantial impact on Arizona under the leadership of the next president and CEO,” Jewett said. The Flinn Foundation was established in 1965 by Dr. Robert Flinn and his wife, Irene, to improve the quality of life in Arizona. Robert Flinn, a leading cardiologist, headed the departments of cardiology and electrocardiography at St. Joseph’s Hospital in Phoenix. He was chief of the medical staff at St. Joseph’s and at Phoenix Memorial Hospital, president of both state and county medical societies, and co-founder and first president of the Arizona affiliate of the American Heart Association. Irene Flinn was a woman of considerable wealth and generous philanthropy. Dr. Flinn died in 1984 at age 87; Mrs. Flinn in 1978 at age 78.


News Article | February 15, 2017
Site: www.nature.com

C57BL/6N mice, ICR mice and Wistar rats were purchased from SLC Japan (Shizuoka, Japan). All animals were maintained under specific pathogen-free conditions. All animal experiments were approved by the Insititutional Animal Care and Use Committee, and performed in accordance with the guidelines of the University of Tokyo and the National Institute for Physiological Sciences. Diabetes was induced in 8-week-old C57BL/6N male mice by intravenous injection of 150 mg kg−1 of STZ. Mice with nonfasting blood glucose levels over 350 mg dl−1 1 week after STZ administration were used. Embryo culture and manipulation are described11. Rodent islets conventionally are isolated by collagenase perfusion of the pancreata through the common bile duct. However, the pancreata of Pdx1mu/mu chimaeric rats could not be perfused in this way because the pancreaticobiliary junction was maldeveloped in all (Extended Data Fig. 5). Therefore, we isolated islets by digestion of minced pancreata with collagenase. Pancreata removed from interspecific chimaera were inflated by interstitial injection of Gey’s balanced salt solution (GBSS; Sigma-Aldrich). GBSS-filled pancreata were minced using scissors. Small pieces of chopped pancreata were digested with collagenase XI (Sigma-Aldrich) to release islets from exocrine tissue. After 6–8 min incubation, islets were picked up using glass micropipettes and transplanted beneath the kidney capsule of 10-week-old male mice with STZ-induced diabetes, as previously described11. To prevent acute graft rejection, 0.5 mg per g (body weight) per day of tacrolimus, was injected intraperitoneally on the day of transplantation and on each of the following 4 days, in addition to an anti-inflammatory cocktail (all components, Affymetrix) containing anti-mouse interferon-γ mAb (rat IgGκ, 16-7312, clone R4-6A2), anti-mouse tumour necrosis factor-α mAb (rat IgG1κ, 16-7322, clone MP6-XT3) and anti-mouse IL-1β (hamster IgG, 16-7012, clone B122). The mRNA of TALENs (left and right) and rat Exo1 were generated by in vitro transcription. Linearized plasmids were transcribed from T7 promoter using mMESSAGE mMACHINE T7 ULTRA Transcription Kit (Thermo Fisher Scientific) and resultant mRNAs were cleaned up by MEGAclear Kit (Thermo Fisher Scientific). 3 or 10 ng μl−1 of each mRNA was prepared by dilution in RNase- free-water and mixture of right TALEN, left TALEN and Exo1 were injected into the male pronuclei of zygotes by microinjection, as previously reported18. TALEN potential off-target sites were predicted by TALENoffer software. We chose 21 candidates (5 in exonic loci, 13 in intronic loci, 3 in intergenic loci) from TOP200 candidates19. We performed PCR amplification of genomic DNA from Pdx1+/muA, Pdx1+/muB and wild-type Wistar rats, subjecting the amplicons to Sanger sequencing. Genomic DNA was isolated from fluorescent-marker-negative cells isolated by FACS from chimaeric-rat blood samples. The TALEN target region of Pdx1 was amplified by PCR using the following primers: (forward) 5′-GCTGAGAGTCCGTGAGCTGCCCAG-3′ and (reverse) 5′-GGAACGCTTAAAGATCGTAGCAGC-3′). The PCR products were sequenced. Total RNA was isolated from duodenum of Pdx1muA/muB mice and reverse-transcribed by Superscript III reverse transcriptase (Thermo Fisher Scientific) with oligodT primer. Pdx1muA or Pdx1muB full-length cDNA were amplified by PCR using the following primers: (forward) 5′-GGCGCTGAGAGTCCGTGAGCTGC-3′ and (reverse) 5′-TTTTTTTTTTTTTTTGAAACCTCAAACAG-3′. Nonfasting blood glucose levels were determined (Medisafe-Mini glucometer; Terumo) weekly after islet transplantation. GTTs in overnight-fasted chimaera rats was conducted 0, 15, 30, 60 and 120 min after intraperitoneal injection of glucose (50% d-glucose solution, 2.5 g per kg body weight). Tail-vein blood was sampled by phlebotomy. Non-fasting serum mouse or rat c-peptide levels were analysed by enzyme-linked immunosorbent assay (ELISA) (mouse c-peptide ELISA kit, Shibayagi and Morinaga Institute of Biological Science; rat c-peptide ELISA kit, MERCODIA AB). Serum was isolated from 10-week-old Pdx1muA/muB + mPSCs chimaeras, C57BL/6N mice and Wistar rats. Serum was obtained from STZ-treated diabetic mice transplanted with mouseR islets 260 or 372 days after transplantation. SGE2 (EGFP-expressing mES cells) were derived from blastocysts generated from mating C57BL/6N female mice with C57BL/6N-Tg male mice (CAG-EGFP) (SLC Japan). mRHT (mES cells) were derived from blastocysts generated from mating male and female H2B-tdTomato knock-in mice with human histone H2B and tdTomato fusion gene in the mouse ROSA locus (T.K., unpublished data). Wlv3i-1 (rES cells) and GT3.2 (miPSCs) have been previously described11, 31. Maintenance of mPSCs and rPSCs has been previously described32, 33. Briefly, mPSCs were cultured on mitomycin-C-treated mouse embryonic fibroblasts in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 0.1 mM 2-mercaptoethanol, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 1,000 units per ml of mouse leukaemia inhibitory factor (all Thermo Fisher Scientific) and 1% l-glutamine-penicillin-streptomycin (Sigma-Aldrich). rPSCs were cultured on mitomycin-C-treated mouse embryonic fibroblasts in N2B27 medium supplemented with 1 μM mitogen-activated protein kinase inhibitor PD0325901 and 3 μM glycogen synthase kinase inhibitor CHIR99021 (both Axon Groeningen). All PSC lines were authenticated by chimaera formation. These cell lines were not contaminated with mycoplasma. Isolated pancreata and islets were fixed in 4% paraformaldehyde in phosphate-buffered saline solution (PBS). Paraffin-embedded sections were incubated with blocking buffer (Active Motif) for 1 h at room temperature. The sections were incubated with primary antibodies, diluted in blocking buffer for 1 h at room temperature, and washed three times with PBS. They were then incubated with secondary antibodies for 1 h at room temperature. Primary antibodies used were guinea pig anti-insulin (Abcam; ab7842), rabbit anti-glucagon (Nichirei Bioscience, 422271), rabbit anti-somatostatin (Nichirei Bioscience 422651), rabbit anti-cytokeratin 19 (Abcam; ab52625, clone EP1580Y), mouse anti-amylase (SantaCruz; SC-46657, clone G-10) and goat anti-GFP (Abcam; ab6673), with Alexa-488-, Alexa-546-, and Alexa-633-conjugated secondary antibodies (Thermo Fisher Scientific). After antibody treatment, sections were mounted with Vectashield (Vector Laboratories), a mounting medium containing DAPI (Thermo Fisher Scientific) for nuclear counterstaining, and sections were observed under fluorescence microscopy. Three to five sections per slide were imaged and processed using Image J. For detection of lymphoid infiltration, DAB immunohistochemistry was performed with rabbit anti-CD3 (Abcam; ab5690) and rabbit anti-CD11b (Bioss Inc.; bs-1014R). Islets or small pieces of kidney that included transplanted islets were dispersed into single cells with collagenase type1A (Sigma-Aldrich). Dispersed cells stained with phycoerythrin (PE)-conjugated anti-mouse CD31 (Thermo Fisher Scientific; A16201, clone 390) or allophycocyanin (APC)-conjugated anti-rat CD31 (Thermo Fisher Scientific; 50-0310-82, clone TLD-3A12) were subjected to FACS CantoII analysing (BD Biosciences). Data were collected for all of the dispersed cells and analysed. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Sample size was estimated on the basis of previous publications. Statistical significance was calculated by F-test and Student’s t-test (compare two groups) and the similarity to the Mendelian ratio was analysed by chi-square test (with Excel and Graphpad Prism software). P < 0.05 was considered to be statistically significant. Data are presented as mean ± s.d. Immunohistochemistry and flow-cytometry studies were repeated three times independently with similar results. All relevant data that are included with this study are available from corresponding auther upon reasonable request.


News Article | February 15, 2017
Site: phys.org

The armyworm has already caused damage to staple crops in Zambia, Zimbabwe, South Africa and Ghana, with reports also suggesting Malawi, Mozambique and Namibia are affected. Experts say it appears to be the first time that the "fall armyworm" species from the Americas has caused widespread damage in Africa. "So, farmers do not know really how to treat it," said David Phiri, the UN Food and Agriculture Organization's coordinator for southern Africa. "Nobody seems to know how it reached Africa," he said, adding that it started in places like Nigeria and Togo, which had it last year. One theory is that the caterpillars arrived in Africa on commercial flights from South America or in plants imported from the region. The caterpillars eat maize, wheat, millet and rice—key food sources in southern and eastern Africa, where many areas are already struggling with shortages after the most severe drought in recent years. Experts from 13 countries will spend three days at the summit in the Zimbabwean capital forming a battle plan to defeat the pests. The armyworm is "spreading rapidly" in Africa and could threaten farming worldwide, the Centre for Agriculture and Bioscience International (CABI) warned last week. It said maize is particularly vulnerable to the larvae, which attack the crop's growing points and burrow into the cobs. Unlike the native African armyworm, the fall armyworm does not "march" along the ground in huge numbers seeking more food, the FAO said. "This sequence of outbreaks began in mid-December 2016 in Zambia," Kenneth Wilson, professor at Lancaster University in Britain, wrote in a briefing paper Monday. "It is now as far south as South Africa. Because armyworms feed on many of the staple food crops they have the potential to create food shortages in the region." The fall armyworm also attacks cotton, soybean, potato and tobacco fields. Chemical pesticides can be effective, but fall armyworms have developed resistance in their native Americas. "You use different methods. One of them is pesticides, another is to use biological control. Another is to use natural control, like digging trenches around the farm (or) natural predators, like birds, to eat those worms," said Phiri. "If it is a small level of the worms, it's easy to control, using pesticides. Otherwise, it's very difficult to control it, so they will have to use different methods—including sometimes burning the crops." Zimbabwe's deputy agriculture minister Davis Marapira confirmed to AFP that the pest had been detected in all of the country's 10 provinces. "The government is helping farmers with chemicals and spraying equipment," Marapira said. The FAO, which is hosting the Harare meeting, said armyworm outbreaks combined with current locust problems "could be catastrophic" as southern Africa has yet to recover from droughts caused by the El Nino climate phenomenon. In December, Zambia deployed its national air force to transport pesticides across the country so that fields could be sprayed.


News Article | February 15, 2017
Site: www.eurekalert.org

Inspired by the hair of blue tarantulas, researchers from The University of Akron lead a team that made a structural-colored material that shows consistent color from all viewing directions. This finding overturns the conventional wisdom that long-range order photonic structures are always iridescent, opening new potential to mass produce structural colors because highly ordered designs are easy to scale-up and manufacture. Bor-Kai (Bill) Hsiung and his colleagues at UA, Ghent University, Karlsruhe Institute of Technology and the University of Nebraska-Lincoln published their research, which is featured on the cover of the January 2017 journal of Advanced Optical Materials. "Structural colors are more vibrant and durable than the pigments used in most human-made products," explained Hsiung, the lead author of this research and a Biomimicry Fellow in the Integrated Bioscience Ph.D. program at The University of Akron. "They are produced by optical effects when light interacts with nanostructures that are about the same size as the wavelength of light." Think of a peacock, or a butterfly. The problem is that most structural colors are strongly iridescent, changing color when viewed from different angles. It's beautiful out in nature, but not very functional when we're watching television and we move to a new seat." The team first discovered that many vibrant blue tarantulas do not show iridescence even though the spiders use nanostructures to produce those colors. Since the spider's blue color is not iridescent, Hsiung's team suggested that the same process could be applied to make pigment replacements that never fade, as well as to help reduce glare on wide-angle viewing systems in phones, televisions and other devices. As they dug deeper, they found that the hairs of some species of blue tarantulas show a special flower-like shape that they hypothesized reduced the iridescent effect resulting from periodic structures. Then, thanks to the crowdfunding push they received earlier, they were able to test this hypothesis using a series of computer simulations and physical prototypes built using cutting-edge nano-3D printing technology. Their color produced by the 3D printed structures has a viewing angle of 160 degrees, the largest viewing angle of any synthetic structural colors demonstrated. "These structural colorants could be used as pigment replacements - many of which are toxic - in materials such as plastics, metal, textiles and paper, and for producing color for wide-angle viewing systems such as phones and televisions," Hsiung said.


News Article | February 21, 2017
Site: www.marketwired.com

NEW YORK, NY--(Marketwired - February 21, 2017) - Taglich Brothers, Inc. announces it initiated coverage of AYTU Bioscience, Inc. AYTU Bioscience, Inc. ( : AYTU), headquartered in Engelwood, Colorado, was formed in April 2015 through a reverse triangular merger with two companies that were formed in 2013. Shortly after the merger, the company, which was formed in 2002, changed its name from Rosewind Corporation to Aytu Bioscience. The company's principal pipeline product, MiOXSYS, acquired with its merger, is CE-marked but not yet cleared in the US. To jump start its commercialization, AYTU acquired the radiolabeled imaging agent ProstaScint (May 2015) for prostate cancer diagnosis, and an oral liquid antimicrobial (October 2015), Primsol, approved for the treatment of uncomplicated urinary tract infections. ProstaScint and Primsol made full-year revenue contributions last year (ending June 2016), accounting for most of the company's product revenue in FY2016. In July 2016, the company also acquired the US rights to Natesto, a testosterone replacement hormone that is cleared in the US and in some overseas markets for the treatment of hypogonadism. Natesto, launched early this fiscal year, could contribute significantly to FY2017 revenue. Aytu has expanded a sales force that is focused on marketing to urologists and, in the case of Natesto, also to endocrinologists. The product line aims to treat or diagnose conditions in substantial patient populations that are growing steadily due in part to demographic trends. These target patient populations seek treatment mainly from urologists, which represent a single call point that can be more easily targeted as they tend to be more concentrated in urban centers in the most populous states in the US. As all of its manufacturing is done by a contract manufacturer or the companies that its products were acquired from, AYTU can devote most of its efforts to marketing and raising additional financing. The complete 19-page report is available at www.taglichbrothers.com. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report. All research issued by Taglich Brothers, Inc. is based on public information. All research issued by Taglich Brothers, Inc. is based on public information. In November 2016 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of the creation and dissemination of reports. After publication of the initial research report the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 monthly for a minimum of three more months for such services. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.


News Article | February 15, 2017
Site: www.marketwired.com

KELOWNA, BC--(Marketwired - February 08, 2017) - Lexaria Bioscience Corp. ( : LXRP) ( : LXX) ("the Company" or "Lexaria"), through its wholly owned Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions. Lexaria believes that results from this scientific collaboration could motivate license adoption of Lexaria's patented flavour masking and nutrient delivery enhancement technology, including but not limited to the vitamin, pain reliever and nicotine sectors. Lexaria's technology is patented in the US, and patent pending in Canada and in 41 other countries around the world. Under the agreement, Lexaria and the National Research Council will both provide up to CDN$125,000 in funding for this research, a total investment of up to $250,000. The master research agreement has an 18-month term, during which a number of shorter-term studies will be undertaken. The collaboration will investigate and define the chemical nature of the molecular association that Lexaria`s patented technology is believed to effectuate between lipophilic active agents and fatty acids as solubility and bioavailability enhancing agents. Effective delivery of lipophilic active agents spans across industry sectors such as, food, vitamins, pharmacy and more, which are multi-billion dollar opportunities. Prospective lipophilic active agents to be investigated under the research agreement include cannabinoids (e.g., cananbidiol "CBD" and tetrahydrocannabinol "THC"), fat soluble vitamins, non-steroidal anti-inflammatory drugs ("NSAIDs") and nicotine, as described in Lexaria`s issued and pending patent applications as well as potentially other high value bioactives to be determined. The research agreement also provides for possible licensing of any arising, non-competing Lexaria intellectual property to NRC or its sub-licensees on terms to be defined in the future as applicable. "This co-funded research agreement with the National Research Council of Canada is a major achievement for us," said John Docherty, President of Lexaria Bioscience Corp. "Having the privilege to work within their high caliber facilities alongside their expert scientists will allow Lexaria to further advance the characterization and commercial potential of its technology in the fastest way possible for a company of our size. Furthermore, the fact that they have a Level 2 dealer`s licensed facility in Canada in which some of this work can be conducted is of particular importance, thereby allowing us to advance research on controlled substances with ease." "The National Research Council's support in the development and commercialization of our technology is highly validating for our Company," said Chris Bunka, CEO of Lexaria Bioscience Corp. "Positive findings from this joint investigation will be of tremendous value to Lexaria in order to broaden the scientific understanding of our intellectual property suite and support our abilities to attract additional strategic licensees across the greater therapeutic foods, dietary supplements and pharmaceutical sectors." Lexaria intends to commercialize its technology for widespread use by markets throughout the world, including over the counter pain remedy sector, vitamins and food supplements, and even the nicotine industries and more. To achieve that, this undertaking of fundamental research will enhance the Company's ability to enter into these distinct market sectors. Additional information will be released regarding completion of the joint research initiatives to be conducted under this research agreement as they are confirmed and available. Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the master collaborative research agreement with the National Research Council of Canada will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors or as a result of the agreement. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements, nor that Lexaria's technology will deliver any improvement in taste or bioavailability with any reliability nor across any product category. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever, nor that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova™ products are not intended to diagnose, treat, cure or prevent any disease. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


News Article | February 17, 2017
Site: www.accesswire.com

KELOWNA, BC / ACCESSWIRE / February 17, 2017 / Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has received US$57,001.80 from the exercise of stock options previously granted. The stock options were exercised at prices of US $0.14 and US$0.2273, for a total of 366,000 common shares being issued. All options are being exercised by third parties who are neither officers nor directors of the Company. As per a contract entered in July 2016, the Company is obligated to pay a US$4,000 monthly fee to a director. The Company and the director have agreed to settle the outstanding amount of US$16,000 for the four months to February 28, 2017 through the issuance of 29,091 restricted common shares. No commissions or placement fees have been paid related to the funds received from this option exercise. Proceeds will be used for general corporate purposes. The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. FOR FURTHER INFORMATION PLEASE CONTACT: This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process, and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods and ViPovaTM products are not intended to diagnose, treat, cure, or prevent any disease. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


KELOWNA, BC--(Marketwired - February 27, 2017) - Lexaria Bioscience Corp. ( : LXRP) ( : LXX) (the "Company" or "Lexaria") is pleased to announce it has received a Notice of Acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017. This establishes Lexaria's first successful acceptance for patent issuance outside of the USA, in what the Company expects will be a series of successful international patent awards. The Notice of Acceptance covers Lexaria patent application entitled "Food and beverage compositions infused with lipophilic active agents and methods of use thereof", which has been accepted with the same set of claims previously issued in US Patent No 9,474,725 specific to non-psychoactive cannabinoids. Lexaria is very pleased with the rapid advancement of its patent claims by the Australian Patent Office and notes Australia's recent federal legislative success in opening the medical cannabis market. Like Canada, the medical cannabis market in Australia is federally legal. "Lexaria's technology is needed not just in the US, but throughout the global cannabis sector, which is why we have patent applications in place in 42 countries around the world," said Chris Bunka, CEO. "Our international applications offer the safety of unparalleled diversification to our supporters that even individual national market leaders cannot offer." The accepted patent application includes a series of Lexaria's method claims for combining non-psychoactive cannabinoid lipophilic active agents together with a bioavailability and taste enhancing oil by way of dehydration or lyophilization, and doing so in contact with a food product substrate material. Lexaria still has a number of additional patent applications undergoing review by the USPTO and patent application continuations planned in order to further broaden its expected set of compositional and method patent claims regarding the technology for application with other molecules such as psychoactive cannabinoids; vitamins; NSAIDs; and Nicotine. The Company continues to thank its many supporters who have contributed to its intellectual property success. About Lexaria Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. There is no assurance that the expected Australian patent granting will occur in June 2017 or at any point in the future and there is no assurance that any additional patents will be granted in the USA or in any other global location. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods and ViPova™ products are not intended to diagnose, treat, cure or prevent any disease. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Loading Bioscience collaborators
Loading Bioscience collaborators